Pharmaceutical Market Research Articles

МАРКЕТИНГОВЫЙ АНАЛИЗ АССОРТИМЕНТА ОСНОВНЫХ МОНОПРЕПАРАТОВ, ПРИМЕНЯЕМЫХ ДЛЯ ТЕРАПИИ РАССТРОЙСТВ СНА

In recent years, many studies have noted that the number of occurrence of various sleep disorders is increasing among the population, while such problems as self-medication, untimely access to a doctor, the presence of concomitant diseases, the development of acute forms of disorders into chronic ones are highlighted, all this affects the quality and life expectancy of the population and makes it relevant to study pharmacotherapy of drugs for the treatment of these disorders in the field of pharmaceutical care [1-6; 11]. The purpose of the study was to establish a list and conduct a marketing analysis of the assortment of the main groups of monopreparations used for the treatment of sleep disorders presented on the domestic pharmaceutical market for their subsequent use in more extensive comprehensive marketing research in the context of sleep disorder therapy. The materials for the study were data from the State Register of Medicines and regulatory documents reflecting the attitude of objects to accounting and control of their sale on the market. The following methods were used: comparisons, systematization, grouping, statistics, as well as structural and assortment analyses. The article presents the results of a study of the Russian market of monopreparations of this orientation. The systematization of the main monopreparations was carried out, as a result, 7 groups were identified, which include 25 international nonproprietary names of medicines represented by 78 trade names, the proportion of manufactured drugs within each group and relative to the total number of trade names were calculated. The next step was to analyze the conditions for the release of drugs, their inclusion in lists reflecting accounting and control during implementation in accordance with regulatory documentation. In conclusion, it is noted that the obtained ranking data and the corresponding calculations will serve as a basis for further research in the field of the pharmaceutical market of drugs used for sleep disorders.

Drug-drug interactions of empagliflozin and dapagliflozin

Abstract Introduction The sodium glucose co-transporter2-inhibitors dapagliflozin (Dapa) and empagliflozin (Empa), initially developed as antihyperglycemic agents, are increasingly also prescribed for non-diabetic patients with heart failure (HF). Glucuronidation by uridine-diphosphate glucuronosyltransferase (UGT)1A9 is the main mechanism of metabolism of Dapa, whereas Empa is eliminated mainly by excretion. Both Dapa and Empa are substrates of P-glycoprotein. The risk for drug-drug interactions (DDI) of Empa and Dapa is assumed to be low. Aim of this study was to summarize reports of DDI of Empa and Dapa from the literature. Methods Search-terms in PubMed were "drug-drug interaction" and AND "sodium glucose co-transporter2-inhibitors" OR "SGLT2" OR "dapagliflozin" OR "empagliflozin". The drugs were classified according the Anatomical Therapeutic Chemical (ATC) system. Included were randomized trials, pharmacovigilance studies, case series, case reports, studies in healthy subjects and in vivo data. The funding of the study and the disclosures of the authors were registered. Results In 45 reports DDI of Empa and Dapa with 29 drugs were described (Table). According to the ATC system, these were drugs for the alimentary tract and metabolism (n=5), blood and blood forming organs (n=2), cardiovascular system (n=11), genitourinary system and sex hormones (n=2), antiinfectives (n=2), antineoplastic and immunomodulating agents (n=3), musculo-skeletal system (n=2) and nervous system (n=2). The reports comprised studies in healthy subjects (n=28), case reports (n=7), case series (n=6), pharmacovigilance studies (n=2), a subgroup analysis of a randomized trial (n=1) and in vivo data (n=1). Most of the reports found no clinically relevant DDI (n=32). Dapa and Empa both had a synergistic diuretic effect with bumetanide, and led to severe infections when combined with the interleukin-17-inhibitors secukinumab or ixekizumab. Empa administered with intravenous iron was reported to increase cell-iron availability, with lithium to reduce lithium exposure and with valproate to increase valproate exposure. Dapa administered with sacubitril-valsartan was reported to lead to severe hypotension, with linezolid to pancytopenia, with donafenib to an increased exposure to donafenib, with rifampicin to a reduction and mefenamic acid to an increase in Dapa exposure. Of the 45 reports, 33 were funded by a pharmaceutical company marketing Dapa or Empa and 33 had authors with conflicts of interest with pharmaceutical companies marketing Dapa or Empa. Conclusions Most data about DDI of Empa and Dapa derive from studies in healthy subjects and from the marketing companies. The clinical relevance DDI of Empa and Dapa in polymorbid patients with polymedication is largely unknown. There is an urgent need for independent studies on DDI of these drugs in diabetic and non-diabetic patients with HF.Table

The marketing promotion in the pharmacutical sector in Kosovo- case study

The paper addresses the issues that have to do with the use of marketing and give a general overview for the pharmaceutical industry, the main marketing concepts, identify the importance of marketing in promoting sales of pharmacy companies, understand which strands are used to promote sales and satisfy the needs of consumers in terms of improving their health. In addition, the paper elaborates the development of the pharmaceutical sector in Kosovo, the competition between pharmaceutical producers and distributors, the strategies that firms use to promote products and services, increase of quality of medicines, price reduction and other issues. The objective of the paper is to explain how pharmaceutical marketing is carried out by focusing more on the communication and romotional techniques used, to give an overview of the functioning of this sector and to identify the importance of promotion in promoting sales. The methodology used is based on comparative analysis through the use of primary and secondary sources. For analysis purposes, a structured questionnaire was prepared for pharmaceutical products, which was distributed physically to the pharmaceutical workers. Scientific literature, local and international official reports and other relevant sources were also used. The results and findings of the research show that promotion has a significant impact on promoting sales.

Pharmaceutical Marketing Management in India

Background: In order to identify key tactics and their gaps, the researcher self- designed questionnaire responses from 80 respondents (who either work at managing level in a pharmaceutical company or own their own firm) on Google through convenience sampling across several areas in India. Additionally, the researcher solicited consumer input on marketing assistance, strategies, and tools. We are going to present research on how pharmaceutical firms' marketing tactics change over time as they transition from one to other. It will additionally shine light on the many marketing techniques and tools that pharmaceutical businesses use. Results: A comprehensive cohort comprising 160 patients satisfying the criteria was included in the study. The duration of the study was six months, and the data were collected from the Department of Nephrology of a Government Medical College. Businesses must use digital marketing, or digital devices for marketing (TAB), to improve efficient advertising after studying pharmaceutical marketing strategies and proposing various strategies for conversation. Digital platforms also play a significant role in facilitating effective feedback and surveys related to marketing strategies. For the healthcare sector to effectively communicate and implement strategies, medical representatives must rotate on a regular basis. The supply chain pricing strategy must also adapt to local requirements in order to enhance sales development. The pricing plan for the supply chain must be adjusted to the demands of the region in order to boost sales. In the pharmaceutical sector, developing new medicines and improving existing ones are necessary to boost sales and generate income. This study includes many details and outcomes that need to be analysed further to improve the current pharmaceutical scenario. Work must be done on quality, the use of advanced techniques, and the implementation of new schemes that benefit the MR team

Analysis of Financial Performances for Merck&Co: Comparison with Johnson&Johnson, Pfizer, and Bristol-Myers Squibb

Abstract: Medicines and medical resources are necessities of human society, and human beings often rely on them to speed up recovery or save lives. Especially since the society has just experienced an epidemic, namely COVID-19, the pharmaceutical industry is often in the spotlight. The prospects of the pharmaceutical industry are optimistic, and people often make profits by purchasing a company's stock. This study will analyze and evaluate the operating status of the four leader companies in the pharmaceutical market through data and theories, in order to figure out the most suitable company to buy shares. By comparing various data, Bristol-Myers Squibb's stock is the most suitable to buy. Because it has great potential in the future, high profitability, and high operation efficiency. The significance of this study is to enable people to discover companies worth investing in, provide professional advice to buyers, promote audiences for worthy companies, and discover companies with development prospects for the market.

How promotion mix helps sustain brand sales during market transitions: insights from the pharmaceutical industry

Purpose Pharmaceutical marketers use detailing, sampling and direct-to-consumer advertising (DTCA) to promote a branded prescription drug (brand drug) to health-care professionals and consumers. These promotion mix elements help raise brand awareness, increase prescription likelihood and guard a product market against competing brand drugs. However, the extent to which these elements remain effective when a brand drug goes off patent and its marketing exclusivity expires, allowing low-price generics to enter the market, remains unclear. This study aims to explore the effectiveness of promotion mix elements before and after the market entry of a generic drug. Design/methodology/approach The authors collected and analyzed a panel data set of 41 brand drugs from 7 therapeutic classes between 2007 and 2014 (3,201 observations) using the two-stage control function approach to address potential endogeneity. Findings The effectiveness of promotion mix elements changes significantly, but not in a universally uniform way, during a market transition. Detailing and DTCA are increasingly effective after a brand drug’s generics enter the market. In contrast, sampling is more effective before the market transition. The positive effects of sampling on brand sales are stronger when the price of a brand drug is higher than the average price of its competing brands. Sampling also helps amplify the positive influences of detailing and DTCA on brand sales. Research limitations/implications This study shows that pharmaceutical promotion is not equally effective in the brand drug market with/without generic competitors. Detailing and DTCA are increasingly effective when generic competition intensifies. In contrast, the distribution of free drug samples is less effective after more generic drugs enter the market. Practical implications Incumbent brands’ promotion expenditures often drop dramatically when the expiration of their patents is near, a practice that likely continues after generics enter the market. Taking into consideration these industry norms and their findings, the authors suggest that promotional decisions during a market transition should not overly focus on cutting promotional expenditures across the board. Since a firm’s promotional expenditure tends to be expensive, factoring in information on the effectiveness of each promotion mix element helps marketers make well-informed strategic decisions on resource allocation during the transition from a market without generics to a market with generics. Originality/value Previous studies do not explicitly account for structural changes in the brand drug market over time. However, the expiration of patent and marketing exclusivity marks a transitional period in which a brand drug eventually competes with its generic counterparts. Given the criticality of such structural change, the authors examine brand drugs’ promotion effectiveness in the presence of their generic counterparts.

Retail Marketing Strategies in the Pharmaceutical Industry and its Approach for Chronic Diseases

The pharmaceutical industry plays a vital role in the healthcare sector, particularly in medication development and distribution to deal with many chronic diseases. Since chronic diseases like diabetes, cardiovascular disorders, and respiratory diseases keep increasing around the globe, there is a huge need for effective pharmaceutical retail marketing, not only creating awareness but also creating access to essential medicinal drugs for the patient. Chronic conditions are quite different from acute conditions, mainly because the disease process is more continuous than discontinuous. Much more extended relationships with the healthcare providers are needed for chronic conditions, and equally, extended relationships with patients are needed to ensure continued management of diseases. In retail marketing strategy, therefore, acquiring appropriate consciousness among patients about their treatment choices, ensuring easy access to the drugs, and following the course of treatment prescribed are thus crucial.

Prospects for optimizing the provision of medicines to pediatric patients based on the development of the pharmaceutical market in the segment of medicines for children

Introduction. The strategy of drug supply to the population of the Russian Federation for the period up to 2025 highlights the need to ensure the rational use, safety and quality of medicines in the range of priority tasks. At the same time, the use of effective medical technologies in pediatric patients is limited both by the range of medicines approved for use in the pediatric population and by the requirements regarding compliance of the pharmaceutical design of the drug with the intended purpose in the target age group. The Russian pharmaceutical market is characterized by a monotonous and persistent tendency to expand the assortment matrix and increase the indicators of real and potential capacity, including in the segment of medicines for pediatrics. However, despite the introduction of new market positions for children into civil circulation, the gradual accumulation of data on the safety, clinical and clinical-economic effectiveness of drugs in the pediatric population, the expansion of the panel of possibilities of production pharmacies, the change in the legal status of registered drugs prescribed by off-label, based on evidence-based experience of use for a new purpose, the issues of the validity of medical prescriptions with an acceptable profile of convincing evidence in relation to pediatric patients in the context of the occurrence and development of a number of pathologies remain open.Aim. The aim of the work was to determine the prospects for optimizing the provision of medicines to pediatric patients based on the development of the pharmaceutical market in the segment of medicines for children.Materials and methods. The information base of the study was made up of data from the Ministry of Health of the Russian Federation for 2010–2022, GRLS as of 01.01.2023, as well as instructions for the medical use of medicines. The target age group of patients was determined in accordance with the Recommendation of the Board of the Eurasian Economic Commission. The content analysis method is used to search scientific literature in the PubMed and eLibrary electronic databases, analyze information from instructions for the medical use of medicines (LP), restrictive lists, GRLS, and the state register of prices for VED. The analysis of morbidity data was carried out using the statistical analysis method. Grouping, ranking and systematization were used in the framework of a structural analysis of morbidity, as well as an analysis of the assortment matrix of drugs for pediatrics within the established market boundaries. Graphical analysis was used to visualize the data. Data processing was carried out using MS Excel 2021.Results and discussion. It was found that in the period from 2010 to 2022, against the background of an increase in the number of children by 11.22 %, there was an increase in primary morbidity by 13.41 % in general. Respiratory diseases prevail in the structure of primary morbidity of children, amounting to 62.61 %. Having analyzed the matrices of the national pediatric code formulary, covering 554 INNs, it turned out that within the pharmacotherapeutic groups J, L, N and P themselves, a decrease in WHO indicators of 16–57 % was recorded. An assessment of the supply on the national market allows us to conclude that 19.55 % of drugs approved for use in pediatric practice are contraindicated in patients under 12 years of age. As a result of the assortment ranking along the route of administration, the predominance of oral forms was established, covering 39.88 % of the assortment matrix.Conclusion. Assessing the dynamics of morbidity in the context of analyzing the structure of the market of drugs for pediatrics allows us to identify priority niches for the pharmaceutical industry in the segments of medicines for the pharmacological correction of respiratory diseases, as well as drugs for the treatment of oncological pathologies, autoimmune disorders, obesity, diabetes mellitus and neurological disorders. The range of medicines presented today, taking into account the forms of release and age restrictions for the treatment of pediatric patients, demonstrates insufficient filling of the market with drugs in special children's dosage forms that ensure acceptability to modern concepts of therapy in pediatrics and accurate dosing of active substances in accordance with the age of the child, which, in turn, reveals the prospects for the pharmaceutical development of medicines with a design that corresponds to the purpose in the target age group.

MARKETING PRIORITIES OF COMPANIES IN THE INTERNATIONAL PHARMACEUTICAL MARKET

The article presents the current trends in the development of the international pharmaceutical market and systematizes the priority areas for implementing marketing approaches of the leading companies. The purpose of this article is to reveal the marketing priorities of international pharmaceutical companies in the context of global challenges. To study this issue, a set of methods was used, namely: analysis and synthesis, statistical method, process and institutionalist approaches, case study.The results of the study show that the international pharmaceutical market is characterized by a high level of dynamism, preservation of the priority share of economically developed countries in revenue generation, significant influence of regulatory mechanisms at the national and international levels, and active processes of economic competition through mergers and acquisitions. The analysis has shown that the modern concept of pharmaceutical marketing goes far beyond the established narrow interpretation as a set of tools for the production, sale and promotion of a pharmaceutical product and is characterized by a high level of adaptability to the challenges of the global marketing environment of the twenty-first century. The article reveals the focus of marketing of leading companies on such priorities as: scaling up marketing budgets, ensuring synergy between marketing and financial indicators of pharmaceutical companies, modernizing communication strategies by optimizing interaction with key opinion leaders, intensifying multichannel marketing, etc.The theoretical significance of the study is to deepen the concept of international marketing in the context of its individual sectoral manifestations, taking into account the influence of global competition, institutional regulations, and technological progress. The practical value is due to the potential of using local or regional benchmarking for domestic companies participating in the international pharmaceutical market. Prospects for further research are considered in the direction of assessing the mechanisms and effects of the introduction of marketing innovations in the field of international pharmaceuticals.

Research of the dynamics of wholesale segment concentration level in the regional pharmaceutical market

Introduction: The study of the competitive environment in the pharmaceutical market is an element of the analysis of the drug supply system. The purpose of the study is to analyze the dynamics of concentration levels in the wholesale segment of the regional pharmaceutical market. Materials and methods: Data on market shares of key players were collected and summarized based on the executed contracts (461 contracts in total) for the supply of pharmaceutical products in the model region. For the competitive analysis of pharmaceutical distributors, the Herfindahl-Hirschman Index (HHIn) calculation method was used. We also used the method of constructing the SV matrix, which has the form of a graph consisting of four quadrants divided on the abscissa scale by the obtained values of market concentration ratios (CRSV) and on the ordinate scale by the values of Hall-Teidman indices (HTSV). Results: Market concentration indicators in the wholesale segment of the regional pharmaceutical market indicate the formation of oligopoly. The constructed SV matrix demonstrated the dynamics of market concentration levels corresponding to the changing economic situation. Based on the results of the analysis, proposals to improve the competitiveness of regional pharmaceutical distributors were formed. Conclusion: The study of the dynamics of market concentration indicators allowed to analyze their state, establish the vectors of their drift, and propose measures to optimize the wholesale supply of pharmaceutical goods.

Functional Disorders of the Biliary Tract and Cholelithiasis: Analysis of a Possible Relationship

Aim: Diagnostic criteria for functional disorders of the biliary tract are presented in the materials of the Rome IV consensus, as well as expert councils of Russian and foreign specialists. Episodes of functional biliary pain are caused by a violation of bile outflow through the cystic duct and sphincter of Oddi. It has been suggested that there is a “biliary continuum” in which in some patients’ biliary dysfunction is transformed into cholelithiasis. Key points. Lithogenic bile is considered as the pathophysiological basis for the development of biliary dyskinesia and cholelithiasis. Lithogenic bile provokes inflammation of low grades in the mucous membrane of the biliary tract, decreased contractility of the gallbladder and impaired relaxation of the biliary sphincters, impaired physiological response to cholecystokinin. Changes in motility of the biliary tract may be associated with the influence of hydrophobic bile salts and impaired eicosanoid metabolism. Hyperplasia of the epithelium and muscle layer, hypersecretion of mucin and cholesterol precipitation further impair the outflow of bile. Experimental data and some clinical observations indicate the possibility of transformation of biliary dysfunction into cholelithiasis. Dysfunction of the sphincter of Oddi is one of the possible consequences of cholecystectomy and, in fact, acts as a variant of postcholecystectomy syndrome. The basis for the treatment of biliary dysfunctions are antispasmodics of different classes, which can be combined with ursodeoxycholic acid. The biliary tract-selective antispasmodic hymecromone has shown high effectiveness in relieving biliary pain, which also has a moderate choleretic effect and the ability to prevent the crystallization of cholesterol in bile and can be used both for functional diseases and for cholelithiasis. The domestic drug hymecromone “Odecromone” entered the pharmaceutical market. Conclusion. There is no doubt that the relevance of further study of the patterns of development of biliary dysfunctions and GI is obvious. The study of this problem will contribute to the development of effective preventive approaches, including in the field of nutraceuticals.

The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness

Abstract It is widely recognized that pharmaceutical marketing contributed to the ongoing US opioid epidemic, but less is understood about how the opioid industry used scientific evidence to generate product demand, shape opioid regulation, and change clinician behavior. In this qualitative study, we characterize select scientific articles used by industry to support safety and effectiveness claims and use a novel database, the Opioid Industry Documents Archive, to determine notable elements of industry and non-industry documents citing the scientific articles to advance each claim. We found that 15 scientific articles were collectively mentioned in 3666 documents supporting 5 common, inaccurate claims: opioids are effective for treatment of chronic, non-cancer pain; opioids are “rarely” addictive; “pseudo-addiction” is due to inadequate pain management; no opioid dose is too high; and screening tools can identify those at risk of developing addiction. The articles contributed to the eventual normalization of these claims by symbolically associating the claims with scientific evidence, building credibility, expanding and diversifying audiences and the parties asserting the claims, and obfuscating conflicts of interest. These findings have implications for regulators of industry products and corporate activity and can inform efforts to prevent similar public health crises.

PDCdb: the biological activity and pharmaceutical information of peptide-drug conjugate (PDC).

Peptide-drug conjugates (PDCs) have emerged as a promising class of targeted therapeutics with substantial pharmaceutical advantages and market potentials, which is a combination of a peptide (selective to the disease-relevant target), a linker (stable in circulation but cleavable at target site)and a cytotoxic/radioactive drug (efficacious/traceable for disease). Among existing PDCs, those based on radiopharmaceuticals (a.k.a. radioactive drugs) are valued due to their accurate imaging and targeted destruction of disease sites. It's demanded to accumulate the biological activity and pharmaceutical information of PDCs. Herein, a database PDCdb was thus constructed to systematically describe these valuable data. Particularly, biological activities for 2036 PDCs were retrieved from literatures, which resulted in 1684, 613and 2753 activity data generated based on clinical trial, animal modeland cell line, respectively. Furthermore, the pharmaceutical information for all 2036 PDCs was collected, which gave the diverse data of (a) ADME property, plasma half-lifeand administration approach of a PDC and (b) chemical modification, primary target, mode of action, conjugating feature of the constituent peptide/linker/drug. In sum, PDCdb systematically provided the biological activities and pharmaceutical information for the most comprehensive list of PDCs among the available databases, which was expected to attract broad interest from related communities and could be freely accessible at: https://idrblab.org/PDCdb/.

Administration, Marketing, Pharmacotherapy of Medicines in Neuro-Oncology

Primary tumors make up 1.5% of all clinical cases. The most vulnerable group is children. Brain neoplasms are the second most common after acute leukemia. According to WHO statistics, men suffer 1.5 times more often than women. Administration, marketing, and pharmacotherapy of medicines in neuro-oncology were carried out. The administration of medicines for neuro-oncology pharmacotherapy in the USA and Ukraine was analyzed. Bevacizumab, Everolimus, Lomustine, Temozolomide were found to be approved in both countries. The issue of administration of medicines for neuro-oncology pharmacotherapy other than as prescribed by a doctor has been studied. The possibility of combined pharmacotherapy in neuro-oncology is indicated. Marketing studies of medicines for neuro-oncology pharmacotherapy have been conducted. The medicines are presented in different dosage forms: solutions for infusions, injections, capsules and lyophilisates. The manufacturers of these medicines are pharmaceutical companies from different countries: India, Germany, Austria, the Netherlands, Ukraine. The majority of medicinal products have indefinite registration in Ukraine, which indicates their availability on the pharmaceutical market for the treatment of neuro-oncological diseases. Causes of tumors, main histological groups of neoplasms, their degree of malignancy, symptoms of tumors, diagnostic methods, therapy and pharmacotherapy in neuro-oncology are given. Further research on the development of methods and preparations of pharmacotherapy for neuro-oncology is relevant and ongoing.

Integrating (Deep) Machine Learning and Cheminformatics for Predicting Human Intestinal Absorption of Small Molecules

The oral route is the most preferred route for drug delivery, due to which the largest share of the pharmaceutical market is represented by oral drugs. Human intestinal absorption (HIA) is closely related to oral bioavailability making it an important factor in predicting drug absorption. In this study, we focus on predicting drug permeability at HIA as a marker for oral bioavailability. A set of 2648 compounds were collected from some early as well as recent works and curated to build a robust dataset. Five machine learning (ML) algorithms have been trained with a set of molecular descriptors of these compounds which have been selected after rigorous feature engineering. Additionally, two deep learning models - graph convolution neural network (GCNN) and graph attention network (GAT) based model were developed using the same set of compounds to exploit the predictability with automated extracted features. The numerical analyses show that out the five ML models, Random forest and LightGBM could predict with an accuracy of 87.71% and 86.04% on the test set and 81.43% and 77.30% with the external validation set respectively. Whereas with the GCNN and GAT based models, the final accuracy achieved was 77.69% and 78.58% on test set and 79.29% and 79.42% on the external validation set respectively. We believe deployment of these models for screening oral drugs can provide promising results and therefore deposited the dataset and models on the GitHub platform (https://github.com/hridoy69/HIA).

A cross-sectional descriptive study: Evaluation of pharmaceutical marketing materials in implementing world health organization guidelines.

A cross-sectional descriptive study: Evaluation of pharmaceutical marketing materials in implementing world health organization guidelines.

REGULATORY AND METHODOLOGICAL PRINCIPLES OF TEACHING STANDARDISATION OF MEDICINES TO FUTURE MASTERS OF PHARMACY IN THE CONTEXT OF DIGITALISATION OF EDUCATION IN UKRAINE

The article substantiates that the strategic vector for ensuring the quality of educational services chosen in Ukraine under martial law has increased the need to update state and local regulations of the educational process, as well as to find effective methodological approaches to teaching higher education students, including the transformation of all teaching and learning materials into digital format and the creation of publicly available knowledge bases on their basis. Based on the analysis of national educational legislation, strategic priorities for the development of the healthcare sector, the article features the regulatory and methodological aspects of the implementation of educational initiatives aimed at improving the level of digital literacy of masters of pharmacy, the practical use of digital technologies in their educational and future professional activities, as well as amendments to educational standards and educational programs in terms of the list of general and special (professional, subject) competencies of the above-mentioned specialties. Generalisation of the content of local acts, websites of higher medical/pharmaceutical education institutions of Ukraine made it possible to identify the main innovations in the organisation of training of future masters of pharmacy, to illustrate these with examples of the introduction of digital technologies in the training of future masters of pharmacy, in particular the discipline «Standardisation of Medicines» at the Bogomolets National Medical University. The leading direction for improving the effectiveness of teaching standardisation of medicines to future masters of pharmacy in the context of digitalisation of higher education in Ukraine is identified, which is to harmonize the regulatory and methodological foundations of this process in accordance with the current and future (post-war reconstruction of the educational sphere) challenges of socio-political life of society, compliance with the security system, the provision of quality educational services in the context of the dynamic deployment of the electronic healthcare system, as well as the desire of government institutions and stakeholders to integrate with the European pharmaceutical market.

Original drugs and generics: are there any differences from the clinician’s point of view?

The article defines the original drug (OD) and examines the history of the appearance of generic drugs (GD), as well as the evolution of views to prove their bioequivalence to OD. The question is considered to what extent pharmacokinetic equivalence can guarantee the clinical equivalence of OD and GD. The data on the rules of registration of GD in different countries are provided. A brief overview of various types of studies comparing the clinical efficacy and safety of OD and GD (meta-analyses, randomized controlled trials, observational studies, description of clinical cases) and their main results is given. The results of a number of observational studies on the replacement of OD with GD and its consequences are presented. The existing system of current quality control of GD is described, numerous cases of recall of GD due to detected violations during their production are given. It is mentioned about individual cases of clinical inefficiency of GD and their side effects identified by the practical physicians. It is concluded that a qualitatively produced GD with proven pharmacokinetic equivalence to OD is able to provide therapy of the same quality as OD. However, numerous cases of the appearance of GD on the pharmaceutical market, which does not correspond to the quality of OD, make us somewhat wary of therapy based on VP. Both the practitioner and the patient should know which of the drugs prescribed by the international nonproprietary name is OD and which is GD.

An In-Depth Analysis of the Influence of Pharmaceutical Marketing Strategies on the Prescription Practices and Decision-Making Processes of Medical Professionals.

The study seeks to explore how pharmaceutical marketing strategies impact doctors’ prescribing habits within the complex relationships between healthcare providers and pharmaceutical companies. Five alternative pharmaceutical products are analyzed across six distinct evaluation parameters to understand the multifaceted impact of marketing efforts. The dataset includes information on marketing spend, prescription rates, and various evaluation criteria such as efficacy, safety, affordability, brand recognition, promotional materials, reputation, and convenience. These parameters are crucial in assessing the comprehensive influence of pharmaceutical marketing on doctors’ decision-making processes. Understanding how pharmaceutical marketing impacts prescription practices is crucial for ensuring patient welfare and safety. It helps in evaluating whether prescriptions are driven by genuine medical needs or influenced by marketing strategies, thus promoting patient-centered care. The study addresses ethical concerns related to the interactions between pharmaceutical companies and healthcare professionals. Uncovering the extent of marketing influence aids in developing ethical guidelines and regulations, fostering transparency and trust in the healthcare system. The COPRAS-G method necessitates identifying selection criteria, evaluating relevant information for these criteria, and creating methods to assess how well the surrogate meets the participants’ needs. Decision analysis involves a Decision Maker (DM) who must consider a specific set of alternatives and choose one from several options, often with conflicting criteria. Consequently, the developed complexity proportionality assessment (COPRAS) method can be applied. The results indicate that Doctor 03 ranked first, while Doctor 05 ranked the lowest.

The influence of a composition based on exometabolites of Saccharomyces boulardii in relation to the pathogenic and persistent properties of fungi of the genus Candida

Clinical manifestations of mycoses vary widely from mild mucosal damage to severe invasive forms. Currently, the pharmaceutical market offers a wide range of antimycotic drugs, including oral and injectable drugs for systemic and external and local use. Varying degrees of effectiveness are due to the chemical structure and pharmacokinetics. A significant problem is the recurrence of mucosal candidiasis. One of the possible solutions to this problem can be considered the use of exometabolites of bacterial or fungal origin, affecting the morphofunctional structures of fungi of the genus Candida spp. The purpose of the study was to obtain cell-free supernatant of Saccharomyces boulardii (S. boulardii) and herbal extracts, which are the basis of a composition with a preventive effect against fungi of the genus Candida. The authors proposed a composition based on the exometabolite of S. boulardii and herbal extracts for the prevention of candidiasis. Propylene glycol served as a control. The effectiveness of the composition was assessed on clinical isolates of C. albicans, C. glabrata and C. krusei isolated from the vaginal biotope at a dilution of 103-106 CFU/mL. At the first stage, we studied the effect of S. boulardii metabolites on the biological properties of fungi. Next, the fungicidal activity of metabolites and extracts was determined by serial dilution against micromycete isolates. At the final stage, the effect of the composition with the most effective extracts was studied. Under the influence of the supernatant of S. boulardii, micromycetes lost the ability to form growth tubes, and a decrease in the catalase activity of Candida spp. was observed both during carriage and disease. Exometabolites significantly reduced the ability to form film in cultures isolated from patients with vaginal candidiasis. The most effective among the extracts were the extracts of St. John’s wort and coriander. The fungicidal properties of the composition were maintained for 12 hours after co-incubation with all isolates of Candida spp. Thus, the composition is effective against both C. albicans and C. non-albicans carriage and disease.